ATHS
MCID: ATH013
MIFTS: 68

Atherosclerosis Susceptibility (ATHS)

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Atherosclerosis Susceptibility

MalaCards integrated aliases for Atherosclerosis Susceptibility:

Name: Atherosclerosis Susceptibility 57
Atherosclerosis 57 12 75 29 55 43 44 15 63 17 72 33
Atherosclerosis, Susceptibility to 57 13 6
Atherogenic Lipoprotein Phenotype; Alp 57
Atherogenic Lipoprotein Phenotype 57
Arteriosclerosis 72
Aths 57
Alp 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant
? same as ldlr


HPO:

32
atherosclerosis susceptibility:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:1936
OMIM 57 108725
ICD9CM 35 440
MeSH 44 D050197
SNOMED-CT 68 38716007
ICD10 33 I25.1 I70
MedGen 42 C1531719
UMLS 72 C0003850 C0004153

Summaries for Atherosclerosis Susceptibility

MedlinePlus : 43 Atherosclerosis is a disease in which plaque builds up inside your arteries. Plaque is a sticky substance made up of fat, cholesterol, calcium, and other substances found in the blood. Over time, plaque hardens and narrows your arteries. That limits the flow of oxygen-rich blood to your body. Atherosclerosis can lead to serious problems, including Coronary artery disease. These arteries supply blood to your heart. When they are blocked, you can suffer angina or a heart attack. Carotid artery disease. These arteries supply blood to your brain. When they are blocked you can suffer a stroke. Peripheral arterial disease. These arteries are in your arms, legs and pelvis. When they are blocked, you can suffer from numbness, pain and sometimes infections. Atherosclerosis usually doesn't cause symptoms until it severely narrows or totally blocks an artery. Many people don't know they have it until they have a medical emergency. A physical exam, imaging, and other diagnostic tests can tell if you have it. Medicines can slow the progress of plaque buildup. Your doctor may also recommend procedures such as angioplasty to open the arteries, or surgery on the coronary or carotid arteries. Lifestyle changes can also help. These include following a healthy diet, getting regular exercise, maintaining a healthy weight, quitting smoking, and managing stress. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Atherosclerosis Susceptibility, also known as atherosclerosis, is related to generalized atherosclerosis and hepatic lipase deficiency, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Atherosclerosis Susceptibility is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Lipoprotein metabolism and Metabolism of fat-soluble vitamins. The drugs Rimonabant and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include Heart and Heart, and related phenotypes are hypertriglyceridemia and myocardial infarction

OMIM : 57 The atherogenic lipoprotein phenotype (ALP) is a common heritable trait characterized by a preponderance of small, dense low density lipoprotein (LDL) particles (subclass pattern B), increased levels of triglyceride-rich lipoproteins, reduction in high density lipoprotein, and a 3-fold increased risk of myocardial infarction (summary by Nishina et al., 1992). The so-called atherogenic lipoprotein phenotype was shown by Austin et al. (1988) to be independently associated with an increased risk for coronary artery disease. Allayee et al. (1998) concluded, furthermore, that there is a genetically based association between familial combined hyperlipidemia (FCHL; 144250) and small, dense LDL particles and that the genetic determinants for LDL particle size are shared, at least in part, among FCHL families and the more general population at risk for coronary artery disease. Juo et al. (1998) concluded from a bivariate segregation analysis of small, dense LDL particles and elevated apolipoprotein B levels (APOB; 107730), which are commonly found together in members of FCHL families, that the 2 traits share a common major gene plus individual polygenic components. The common major gene was estimated to explain 37% of the variance of adjusted LDL particle size and 23% of the variance of adjusted apoB levels. (108725)

PubMed Health : 63 About atherosclerosis: Atherosclerosis (ath-er-o-skler-O-sis) is a disease in which plaque (plak) builds up inside your arteries. Arteries are blood vessels that carry oxygen-rich blood to your heart and other parts of your body. Plaque is made up of fat, cholesterol, calcium, and other substances found in the blood. Over time, plaque hardens and narrows your arteries. This limits the flow of oxygen-rich blood to your organs and other parts of your body. Atherosclerosis can lead to serious problems, including heart attack, stroke, or even death.

Wikipedia : 75 Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.... more...

Related Diseases for Atherosclerosis Susceptibility

Diseases related to Atherosclerosis Susceptibility via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1152)
# Related Disease Score Top Affiliating Genes
1 generalized atherosclerosis 34.9 CRP APOE
2 hepatic lipase deficiency 33.4 APOE APOA1
3 familial lcat deficiency 33.4 APOE APOA1
4 carotid stenosis 33.4 CRP CDKN2B-AS1 APOE
5 carotid artery disease 33.2 CRP APOE APOB APOA1
6 tangier disease 33.1 APOE APOB APOA1 ABCA1
7 peripheral vascular disease 32.6 VCAM1 CRP APOB APOA1
8 cerebrovascular disease 32.5 VCAM1 TLR4 PON1 LDLR CRP APOE
9 peripheral artery disease 31.9 VCAM1 CRP CDKN2B-AS1 APOB
10 aortic aneurysm, familial abdominal, 1 31.8 H19 CDKN2B-AS1 APOE
11 coronary heart disease 1 31.7 PON1 LDLR H19 CRP CDKN2B-AS1 APOE
12 diabetes mellitus 31.6 TUG1 PON1 CRP CDKN2B-AS1 APOB APOA1
13 homozygous familial hypercholesterolemia 31.5 LDLR APOE APOB
14 stroke, ischemic 31.4 TLR4 PON1 CRP CDKN2B-AS1 APOE APOB
15 hyperlipoproteinemia, type iii 31.2 LDLR APOE APOB APOA1
16 macular degeneration, age-related, 1 31.1 CRP APOE APOB ABCA1
17 lipid metabolism disorder 31.1 LDLR CRP APOE APOB APOA1 ABCA1
18 familial hyperlipidemia 31.1 PON1 LDLR APOE APOB APOA1
19 coronary artery anomaly 31.0 PON1 CRP APOB APOA1
20 aortic atherosclerosis 31.0 PON1 LDLR APOE ABCA1
21 acute myocardial infarction 30.9 CRP CDKN2B-AS1 APOB APOA1
22 defective apolipoprotein b-100 30.9 LDLR APOE APOB
23 body mass index quantitative trait locus 11 30.8 PON1 LDLR H19 CRP APOE APOB
24 hypolipoproteinemia 30.8 APOE APOB APOA1 ABCA1
25 takayasu arteritis 30.8 VCAM1 PON1 CRP
26 lecithin:cholesterol acyltransferase deficiency 30.8 LDLR APOE APOB APOA1
27 lipoprotein glomerulopathy 30.7 LDLR APOE APOB
28 hypertriglyceridemia, familial 30.7 APOE APOB APOA1
29 arcus corneae 30.7 LDLR APOE APOB APOA1
30 endometriosis 30.6 H19 ESR1 CDKN2B-AS1
31 xanthomatosis 30.6 LDLR APOE APOB
32 coronary stenosis 30.6 PON1 CRP APOE APOB APOA1
33 periodontitis 30.6 TLR4 CRP CDKN2B-AS1
34 osteogenic sarcoma 30.6 TUG1 HULC H19 CDKN2B-AS1
35 cerebral atherosclerosis 30.5 APOE APOA1
36 proteasome-associated autoinflammatory syndrome 1 30.5 VCAM1 TLR4 CRP ALOX5
37 hyperalphalipoproteinemia 1 30.5 LDLR APOE APOB APOA1 ABCA1
38 hyperlipoproteinemia, type v 30.4 APOE APOB APOA1
39 cervical cancer 30.3 TUG1 TP53COR1 HULC H19 CDKN2B-AS1
40 aortic valve disease 1 30.3 H19 CRP APOB
41 huntington disease-like 1 30.2 APOE APOB
42 arteries, anomalies of 30.2 VCAM1 PON1 LDLR CRP APOE APOB
43 abetalipoproteinemia 30.2 LDLR APOE APOB APOA1
44 diabetes mellitus, noninsulin-dependent 30.2 VCAM1 PON1 CRP CDKN2B-AS1 APOE APOB
45 inherited metabolic disorder 30.2 CRP APOB APOA1
46 arteriosclerosis 30.1 VCAM1 TLR4 PON1 CRP APOE APOB
47 heart disease 29.9 PON1 LDLR H19 CRP APOE APOB
48 vascular disease 29.5 VCAM1 PON1 LDLR CRP APOE APOB
49 myocardial infarction 29.3 TLR4 PON1 LDLR ESR1 CRP CDKN2B-AS1
50 autoimmune lymphoproliferative syndrome 12.6

Graphical network of the top 20 diseases related to Atherosclerosis Susceptibility:



Diseases related to Atherosclerosis Susceptibility

Symptoms & Phenotypes for Atherosclerosis Susceptibility

Human phenotypes related to Atherosclerosis Susceptibility:

32
# Description HPO Frequency HPO Source Accession
1 hypertriglyceridemia 32 HP:0002155
2 myocardial infarction 32 HP:0001658
3 decreased hdl cholesterol concentration 32 HP:0003233

Symptoms via clinical synopsis from OMIM:

57
Cardiac:
increased myocardial infarction risk

Lab:
preponderance of small, dense low density lipoprotein (ldl) particles (subclass pattern b)
increased triglyceride-rich lipoproteins
reduced high density lipoprotein

Clinical features from OMIM:

108725

UMLS symptoms related to Atherosclerosis Susceptibility:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Atherosclerosis Susceptibility according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.35 ABCA1 APOA1 APOB APOE LDLR
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE LDLR

MGI Mouse Phenotypes related to Atherosclerosis Susceptibility:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.9 ABCA1 ALOX5 APOA1 APOB APOE CRP
2 liver/biliary system MP:0005370 9.5 ABCA1 APOA1 APOB APOE ESR1 LDLR
3 pigmentation MP:0001186 8.92 APOB APOE LDLR TLR4

Drugs & Therapeutics for Atherosclerosis Susceptibility

PubMed Health treatment related to Atherosclerosis Susceptibility: 63

Treatments for atherosclerosis may include lifestyle changes, medicines, and medical procedures or surgery. The goals of treatment include: Relieving symptomsReducing risk factors in an effort to slow or stop the buildup of plaqueLowering the risk of blood clots formingWidening or bypassing plaque-clogged arteriesPreventing atherosclerosis-related diseases

Drugs for Atherosclerosis Susceptibility (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 809)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rimonabant Approved, Investigational Phase 4 158681-13-1, 168273-06-1 104850
2
Nitric Oxide Approved Phase 4 10102-43-9 145068
3
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723 149351
4
Phylloquinone Approved, Investigational Phase 4 84-80-0
5
Warfarin Approved Phase 4 81-81-2 6691 54678486
6
Rivaroxaban Approved Phase 4 366789-02-8
7
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
8
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
9
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
10
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
11
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
12 fluindione Approved, Investigational Phase 4 957-56-2
13
Dalteparin Approved Phase 4 9005-49-6
14
Mirabegron Approved Phase 4 223673-61-8 9865528
15
Insulin Detemir Approved Phase 4 169148-63-4 5311023
16
Zinc Approved, Investigational Phase 4 7440-66-6 32051
17
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
18
Propranolol Approved, Investigational Phase 4 525-66-6 4946
19
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
20
Remifentanil Approved Phase 4 132875-61-7 60815
21
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
22
Pravastatin Approved Phase 4 81093-37-0 54687
23
Chromium Approved Phase 4 7440-47-3 27668
24
Acetaminophen Approved Phase 4 103-90-2 1983
25
Saxagliptin Approved Phase 4 361442-04-8 11243969
26
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
27
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
28
Ticlopidine Approved Phase 4 55142-85-3 5472
29
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
30
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
31
Caffeine Approved Phase 4 58-08-2 2519
32
Sevelamer Approved Phase 4 52757-95-6
33 Tomato Approved Phase 4
34
Calcium acetate Approved, Investigational Phase 4 62-54-4
35
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
36
Gliclazide Approved Phase 4 21187-98-4 3475
37
Glyburide Approved Phase 4 10238-21-8 3488
38
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
39
Anthralin Approved Phase 4 1143-38-0
40
Adalimumab Approved Phase 4 331731-18-1 16219006
41
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
42
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
43
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
44
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
45
Racepinephrine Approved Phase 4 329-65-7 838
46
Insulin glargine Approved Phase 4 160337-95-1
47
Insulin Lispro Approved Phase 4 133107-64-9
48
Molsidomine Approved, Investigational Phase 4 25717-80-0
49
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
50
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883

Interventional clinical trials:

(show top 50) (show all 2957)
# Name Status NCT ID Phase Drugs
1 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
2 Phase 3 Study of Atorvastatin Effects on Carotid Atherosclerosis Unknown status NCT00640744 Phase 4 Atorvastatin
3 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
4 Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment Unknown status NCT00912756 Phase 4 cilostazol
5 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
6 Preventive Effects of Ginseng Against Atherosclerosis and Subsequent Ischemic Stroke: A Randomized Controlled Trial Unknown status NCT02796664 Phase 4
7 Homocysteine Lowering and Atherosclerosis Reduction Trial (HART) Unknown status NCT00217178 Phase 4 Vitamins: Folic acid, B6, B12
8 Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
9 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques. Unknown status NCT01773512 Phase 4 Rosuvastatin
10 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
11 The Effect of a Natural Polyphenolic Extract From Pomegrnate (POMX) on the Development of Atherosclerosis in Diabetic Patients Unknown status NCT00470808 Phase 4 POMx
12 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
13 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis Progression and Epicardial Adipose Tissue(EAT) Volume Reduction in Patients With Coronary Atherosclerosis Detected by Coronary CT Angiography(CCTA) Unknown status NCT02360956 Phase 4 Olmesartan medoxomil tablets;Antihypertensive medication (per doctor suggestion)
14 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
15 A 2-year, Open-label, Randomized Study to Evaluate the Efficacy of Rosuvastatin Dosing Adjustment by LDL-C Level Compared to That of 5mg Maintenance Dose in Chinese Patients With Carotid Atherosclerotic Plaques Unknown status NCT02532309 Phase 4 Rosuvastatin (5mg,10mg,20mg);Rosuvastatin 5mg
16 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
17 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
18 A 104-week, Open-label, Single-group Study: Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH) Unknown status NCT00885872 Phase 4 Rosuvastatin (Crestor)
19 The Effect of Dates on Plasma Lipids, Oxidative Stress and the Atherogenicity of Serum in Healthy Adults Unknown status NCT00750789 Phase 4
20 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
21 The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Atherosclerosis Unknown status NCT00963222 Phase 4 vitamin A;placebo
22 To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject Unknown status NCT02098460 Phase 4 Atorvastatin, Probucol, Cilostazol
23 Effect of Atorvastatin on Inflammatory Atherosclerotic Plaques Assessed by FDG-PET Imaging Unknown status NCT00920101 Phase 4 Atorvastatin
24 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
25 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
26 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
27 The Effect of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by T CD4+ Lymphocyte in Atherosclerotic Patients Unknown status NCT01414972 Phase 4 Vitamin A;placebo
28 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
29 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
30 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4
31 Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Randomized Controlled Trial in Patients With Advanced Atherosclerosis. Unknown status NCT00711984 Phase 4
32 the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy Unknown status NCT03230851 Phase 4 aspirin 100mg/d therapy;aspirin 100mg/2d therapy;aspirin 100mg/3d therapy;aspirin 50mg bid therapy;aspirin 75mg/d therapy;aspirin 50mg/d therapy;indobufen 100mg bid therapy
33 Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study Unknown status NCT02299245 Phase 4 rosuvastatin
34 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
35 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
36 Does Rosuvastatin Delay Progression of Atherosclerosis in People With HIV Infection at Moderate Cardiovascular Risk? A Multicentre Randomized, Double Blind Placebo-controlled Trial Unknown status NCT01813357 Phase 4 Rosuvastatin
37 Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
38 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
39 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
40 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
41 Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome Unknown status NCT00988364 Phase 4 Simvastatin;Vytorin;Placebo;Ezetimibe
42 The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation Unknown status NCT02626169 Phase 4 Clopidogrel;Ticagrelor
43 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4 Diltiazem treated group;Bisoprolol treated group;Candesartan treated group
44 Type 2 Diabetes Mellitus: Role of Inflammation and Innate Immunity in The Pathogenesis of Endothelial Dysfunction and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
45 Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism Unknown status NCT00350701 Phase 4 androgel;androgel 10g;placebo
46 Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function Unknown status NCT02584075 Phase 4 Byetta (Exenatide);Glucophage ( Metformin Hydrochloride)
47 Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke Unknown status NCT03252626 Phase 4 Alprostadil;Normal saline
48 Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Unknown status NCT03195153 Phase 4 Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg
49 Endothelial Dysfunction in Systemic Lupus Erythematosus: Its Contribution to Abnormalities in Coronary Perfusion. Unknown status NCT00188188 Phase 4 quinipril
50 Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation - The TOP RACER Trial Unknown status NCT01638078 Phase 4 Thalidomide;Placebo

Search NIH Clinical Center for Atherosclerosis Susceptibility

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cholestyramine
Epoprostenol
Epoprostenol Sodium
Evolocumab
Fluvastatin
Isoxsuprine
Isoxsuprine Hydrochloride
Niacin
Rosuvastatin

Cochrane evidence based reviews: atherosclerosis

Genetic Tests for Atherosclerosis Susceptibility

Genetic tests related to Atherosclerosis Susceptibility:

# Genetic test Affiliating Genes
1 Atherosclerosis 29

Anatomical Context for Atherosclerosis Susceptibility

MalaCards organs/tissues related to Atherosclerosis Susceptibility:

41
Endothelial, Heart, Kidney, Monocytes, Smooth Muscle, Liver, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Atherosclerosis Susceptibility:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Coronary Capillary Plexus Affected by disease
2 Heart Coronary Vessels Affected by disease
3 Endothelium Arteries Arterial Endothelial Cells Affected by disease

Publications for Atherosclerosis Susceptibility

Articles related to Atherosclerosis Susceptibility:

(show top 50) (show all 33532)
# Title Authors PMID Year
1
Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. 9 38 71
14702425 2004
2
Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19. 9 38 8
1731344 1992
3
VEGF polymorphisms and severity of atherosclerosis. 38 71
15937083 2005
4
Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study. 38 71
11894143 2002
5
Multilocus genetic determinants of LDL particle size in coronary artery disease families. 9 8
8644718 1996
6
Aging-related atherosclerosis is exacerbated by arterial expression of tumor necrosis factor receptor-1: evidence from mouse models and human association studies. 8
20421368 2010
7
Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. 71
18413368 2009
8
Vascular endothelial growth factor gene variability is associated with increased risk for AD. 71
15732116 2005
9
Association between estrogen receptor alpha gene variation and cardiovascular disease. 71
14600184 2003
10
Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. 71
11919305 2002
11
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. 71
10369259 1999
12
A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia. 8
9683593 1998
13
Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype. 8
9683614 1998
14
The atherogenic lipoprotein phenotype is not caused by a mutation in the coding region of the low density lipoprotein receptor gene. 8
9184244 1997
15
Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. 71
9062372 1997
16
Low-density lipoprotein subclass patterns and risk of myocardial infarction. 8
3418853 1988
17
Pentraxin-3 and endothelial dysfunction. 17
31331488 2019
18
The burden of critical limb ischemia: a review of recent literature. 17
31308682 2019
19
Cholesterol-embolization syndrome: current perspectives. 17
31371977 2019
20
Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. 9 38
19687018 2010
21
Extracellular phospholipases in atherosclerosis. 9 38
20153800 2010
22
Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis. 9 38
20154064 2010
23
Studies on protective effects of human paraoxonases 1 and 3 on atherosclerosis in apolipoprotein E knockout mice. 9 38
20182519 2010
24
Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis. 9 38
20360257 2010
25
Associations between plasma C-reactive protein levels and the severities of coronary and aortic atherosclerosis. 9 38
20134100 2010
26
MMP2 genetic variation is associated with measures of fibrous cap thickness: The Atherosclerosis Risk in Communities Carotid MRI Study. 9 38
20064641 2010
27
Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. 9 38
20167662 2010
28
Soluble epoxide hydrolase in atherosclerosis. 9 38
20425256 2010
29
Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. 9 38
20444418 2010
30
Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. 9 38
20395699 2010
31
Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. 9 38
20439543 2010
32
Toll like receptor 4 in atherosclerosis and plaque destabilization. 9 38
19900676 2010
33
Association between platelet endothelial cellular adhesion molecule-1 polymorphisms and atherosclerosis: results of a study on patients from northern Italy. 9 38
20370486 2010
34
[Association of the ALOX5AP gene SG13S114 A/T polymorphism with atherosclerosis]. 9 38
20376802 2010
35
Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat. 9 38
19931584 2010
36
Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. 9 38
19896127 2010
37
Interleukin-18 gene polymorphism and markers of subclinical atherosclerosis. The Cardiovascular Risk in Young Finns Study. 9 38
20350254 2010
38
Proteomic profiling in apolipoprotein E-deficient mice during atherosclerosis progression. 9 38
19230958 2010
39
Accelerated atherosclerosis in rheumatoid arthritis: rationale for mannose-binding lectins? 9 38
20197564 2010
40
Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. 9 38
20110287 2010
41
Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis. 9 38
19766217 2010
42
[Effects of PPARgamma agonist on dyslipidemia and atherosclerosis]. 9 38
20158099 2010
43
Regulations of the key mediators in inflammation and atherosclerosis by aspirin in human macrophages. 9 38
20137092 2010
44
[LOX-1 receptor as a novel target in endothelial dysfunction and atherosclerosis]. 9 38
20146162 2010
45
[Roles of PPARgamma in preventing the development of atherosclerosis in LDL receptor null mice]. 9 38
20158089 2010
46
Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. 9 38
20142250 2010
47
Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. 9 38
20124121 2010
48
Characteristics of apolipoprotein M and its relation to atherosclerosis and diabetes. 9 38
19909825 2010
49
Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. 9 38
19910639 2010
50
Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. 9 38
19834878 2010